BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now
Advanced Search

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

18 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.EBI
Janssen Research and Development
1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.EBI
Merck Research Laboratories
Lysine demethylases inhibitors.EBI
Kyoto Prefectural University of Medicine
Structural basis for binding of cyclic 2-oxoglutarate analogues to factor-inhibiting hypoxia-inducible factor.EBI
University of Oxford
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.EBI
Nagoya City University
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.EBI
University College London
Novel Compounds as PHD Inhibitors for Treating Heart, Lung, Liver, and Kidney Diseases.EBI
Smith, Gambrell & Russell
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.EBI
Merck Research Laboratories
Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.EBI
Oxford University
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.EBI
Merck
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.EBI
Cadila Healthcare
1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.EBI
Takeda California
Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancerBDB
Korea Research Institute of Chemical Technology
ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOFBDB
Bolt Biotherapeutics
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory responseBDB
Allergan
Fused cyclopentyl antagonists of CCR2BDB
Janssen Pharmaceutica